Lumera Receives Order from BRI for a ProteomicProcessor Biosensor
Complete the form below to unlock access to ALL audio articles.
Lumera Corporation has announced that Baylor Research Institute (BRI) had agreed to purchase its beta ProteomicProcessor™ Biosensor instrument.
"Dr. Jacques Banchereau's work at the Institute is cutting-edge research in the field of Immunology which focuses on cancer vaccines, autoimmune and infectious diseases, and organ transplantation," said Ron Dudek, Product Development Manager, Bioscience Business Unit.
"We look forward to demonstrating the ProteomicProcessor's high-throughput measurement capability in Dr. Banchereau's multi-faceted program."
"Our label-free technology coupled with our NanoCapture™ high-density microarrays should lower the cost and increase the speed of data acquisition for the life sciences, drug discovery and translational medicine researchers."
Dr. Banchereau's team at Baylor Research Institute, a component of Baylor Health Care System in Dallas, plans to use the ProteomicProcessor™ to measure serum protein levels.
"The strength of this instrument for us is the ability to look at many serum protein levels at the same time without having to label the proteins first," states Dr. Banchereau.
